Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and Myocardial Infarction in Patients with Age-Related Macular Degeneration: A Self-Controlled Case-Series Analysis

[1]  P. Mitchell,et al.  Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme , 2013, British Journal of Ophthalmology.

[2]  D. Preen,et al.  MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS: A Whole Population Study , 2013, Retina.

[3]  Simone Rossi,et al.  Australian Medicines Handbook , 2012 .

[4]  N. Bressler,et al.  CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS , 2012, Retina.

[5]  G. Antes,et al.  A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard , 2012, PloS one.

[6]  C. Bell,et al.  Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. , 2012, Ophthalmology.

[7]  Paddy Farrington,et al.  Mortality and the self‐controlled case series method: Letter to the Editor , 2012, Pharmacoepidemiology and drug safety.

[8]  C. Bell,et al.  Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study , 2012, BMJ : British Medical Journal.

[9]  P. Mitchell,et al.  Age-Related Macular Degeneration and Long-Term Risk of Stroke Subtypes , 2012, Stroke.

[10]  E. Stefánsson,et al.  Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load , 2011, British Journal of Ophthalmology.

[11]  A. Joussen,et al.  The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279 , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  K. Schulman,et al.  Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. , 2010, Archives of ophthalmology.

[13]  G. Quentel,et al.  Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. , 2009, American journal of ophthalmology.

[14]  J. Ruiz-Moreno,et al.  Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. , 2009, Survey of ophthalmology.

[15]  Heather J Whitaker,et al.  The methodology of self-controlled case series studies , 2009, Statistical methods in medical research.

[16]  Takuhiro Yamaguchi,et al.  Cerebrovascular accidents in ranibizumab. , 2009, Ophthalmology.

[17]  C. Anderson,et al.  Trends in Incidence and Outcome of Stroke in Perth, Western Australia During 1989 to 2001: The Perth Community Stroke Study , 2008, Stroke.

[18]  Neil M Bressler,et al.  Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. , 2007, Archives of ophthalmology.

[19]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[20]  Patrick Musonda,et al.  Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.

[21]  Anne E Sales,et al.  Construction and Characteristics of the RxRisk-V: A VA-Adapted Pharmacy-Based Case-mix Instrument , 2003, Medical care.